US 12,246,191 B2
Diffusing alpha-emitter radiation therapy with enhanced beta treatment
Lior Arazi, Tel Aviv (IL); Robert B Den, Merion Station, PA (US); Michael Schmidt, Kfar Saba (IL); Ofer Magen, Hod Hasharon (IL); Itzhak Kelson, Tel Aviv (IL); and Amnon Gat, Matan (IL)
Assigned to Alpha Tau Medical Ltd, Jerusalem (IL)
Filed by ALPHA TAU MEDICAL LTD., Jerusalem (IL)
Filed on Oct. 4, 2023, as Appl. No. 18/480,545.
Application 18/480,545 is a division of application No. 17/549,929, filed on Dec. 14, 2021, granted, now 11,857,803.
Claims priority of provisional application 63/126,070, filed on Dec. 16, 2020.
Prior Publication US 2024/0024701 A1, Jan. 25, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61N 5/10 (2006.01)
CPC A61N 5/1027 (2013.01) [A61N 2005/1085 (2013.01); A61N 2005/1098 (2013.01)] 20 Claims
OG exemplary drawing
 
1. An interstitial source, comprising:
a base suitable for implanting in a tumor; and
radioactive atoms of one or more isotopes, which are attached to the base, wherein the radioactive atoms have a radon release rate of at least 0.5 micro-Curie (μCi) per centimeter length, and emit beta radiation achieving at 2 millimeters from the base an asymptotic dose of at least 10 Gy,
wherein the ratio between the beta radiation asymptotic dose at a distance of 2 millimeters from the device interstitial source, to the radon release rate, is greater than 15 Gy/(μCi/cm).